Merck Serono (Merck KGaA) has signed an exclusive licensing agreement with Affectis Pharmaceuticals of Germany for the development and commercialisation of oral compounds targeting P2X7 receptors. The deal does not include Affectis' lead P2X7 antagonist, AFC-5128, which is in advanced preclinical development, Affectis' CBO Luc St-Onge told Scrip.
Affectis plans to file an IND early next year for AFC-5128, which is being developed to treat multiple sclerosis and neuropathic pain. AFC-5128 belongs to a different series of compounds...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?